Compass Therapeutics (NASDAQ:CMPX) vs. Natera (NASDAQ:NTRA) Head-To-Head Contrast

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and Natera (NASDAQ:NTRA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Profitability

This table compares Compass Therapeutics and Natera’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Compass Therapeutics N/A -49.93% -43.76%
Natera -5.66% -8.61% -5.93%

Analyst Recommendations

This is a summary of current ratings for Compass Therapeutics and Natera, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Compass Therapeutics 1 3 12 1 2.76
Natera 2 2 17 2 2.83

Compass Therapeutics presently has a consensus target price of $9.99, suggesting a potential upside of 1,546.89%. Natera has a consensus target price of $394.31, suggesting a potential upside of 37.17%. Given Compass Therapeutics’ higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than Natera.

Insider & Institutional Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 18.7% of Compass Therapeutics shares are owned by insiders. Comparatively, 5.0% of Natera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Compass Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.

Valuation & Earnings

This table compares Compass Therapeutics and Natera”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Compass Therapeutics $850,000.00 128.54 -$66.49 million ($0.47) -1.29
Natera $2.31 billion 18.08 -$208.16 million ($1.14) -252.17

Compass Therapeutics has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Natera beats Compass Therapeutics on 8 of the 14 factors compared between the two stocks.

About Compass Therapeutics

(Get Free Report)

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research centers on immuno-oncology and other approaches intended to target biological pathways involved in tumor growth and the body’s immune response. One of its investigational programs is CTX-009, a bispecific antibody designed to target DLL4 and VEGF-A, proteins associated with tumor blood-vessel development. Compass is also advancing other antibody programs for potential use against solid tumors.

About Natera

(Get Free Report)

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.